Abstracts | 67 symptoms gradually decreased. Subsequently, we resumed HBO. Combination therapy of TRH and HBO dramatically improved to his premorbid state, except for higher brain dysfunction. After discharge, he underwent rehabilitation at another hospital for approximately five years and returned to work. However, his symptoms of higher brain dysfunction and mood disturbance caused another suicide attempt by CO poisoning. Although he did not demonstrate any severe psychiatric symptoms, except for higher brain dysfunction, MRI and SPECT imaging revealed progressive atrophy and blood flow reduction of both frontal lobes in his brain. Finally, he was unable to return to the community. Conclusion: Administration of TRH may be useful for the interval form of CO poisoning, who is difficult to introduce HBO due to severe psychiatric symptom. Because the interval form of CO poisoning may cause a progressive clinical course with severe brain atrophy and dysfunction, continuing psychiatric care is necessary for the patient.
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The effect of mindfulness based group art therapy on the depression, anxiety and quality of life in Korean patients with breast cancer Medicine and Hospital, Iksan, South Korea, Wonkwang Brain, Behavior and Mental Health Institute Abstract Objective: This is an exploratory, quasi-experimental study to investigate the effects of mindfulness based group art therapy on the depression, anxiety and quality of life in Korean patients with breast cancer. Methods: 24 of 60 patients with breast cancer, aged 35 to 65 who underwent surgery at least 1 year after completed chemotherapy or radiotherapy were randomly assigned to either a control group or experimental group. The experimental group received 90 minutes of mindfulness based group art therapy in weekly sessions over a period of 3 months, while the control group had continued daily routines(no action). Personality Assessment Inventory(PAI) was used to assess the effect of therapy on depression and anxiety. Abstract Novel antiparkinsonian drug Hemantane (N-2-adamantyl hexamethylenimine hydrochloride) (H) was synthesizied and preclinically studied in Zakusov Institute of Pharmacology. Effects of H were proved in animal models of parkinsonism and in pilot clinical study in patients with early Parkinson's disease (PD). At present randomized double-blind placebo-controlled study efficacy and safety of H was evaluated in PD patients.
60 patients with initially diagnosed untreated PD were included. 20 were treated by H 25 mg daily for 16 weeks, 20 received H 25 mg during first 4 weeks and then the dose was increased to 50 mg (25 mg twice a day), 20 patient received placebo (1 or 2 tablets). Efficacy was assessed in Unified Parkinson's Disease Rating Scale (UPDRS) and several other scales. General state, blood pressure, electrocardiogram, blood and urine tests were controlled for safety evaluation.
H was more effective in patients which received 50 mg a day. The decrease of rigidity was more pronounced. In the group "H 50 mg" at the end of treatment index of rigidity was decreased by 41% to the baseline. In the group "H 50 mg" significant decrease in the score of UPDRS III "Motor examination" compared to "Placebo" group was revealed on 8, 12 and 16 weeks, the same as decrease of the total score of the scale. After 16 weeks of treatment significant difference in the total UPDRS score was registered also between "H 50 mg" and "H 25 mg" groups.
The safety of H was proved. Non serious adverse reactions were registered in 10 patients, only 6 were possibly connected with treatment, transient and did not require discontinuation of treatment.
The present study confirmed moderate efficacy of H 50 mg monotherapy in patients with early PD and safety of both daily doses. Clinical trial of H combination with dopamine agonists was recommended.
